{
    "name": "omidubicel",
    "comment": "Rx",
    "other_names": [
        "Omisirge",
        "omidubicel-onlv"
    ],
    "classes": [
        "Hematopoietic Progenitor Cells"
    ],
    "source": "https://reference.medscape.com/drug/omisirge-omidubicel-4000313",
    "pregnancy": {
        "common": [
            "No data are available on use in pregnant females",
            "No animal reproductive and developmental toxicity studies have been conducted to assess whether it can cause fetal harm when administered to pregnant females",
            "Use during pregnancy only if the potential benefit justifies the potential risk to the fetus",
            "Verify pregnancy status of females with reproductive potential "
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "See the prescribing information for medications used for conditioning for information on need for effective contraception in patients who receive a conditioning regimen",
                    "There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of omidubicel in human milk, effect on breastfed infants, and effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Infusion reactions",
                    "description": [
                        "Infusion reactions may be fatal ",
                        "Premedication with antipyretics, histamine antagonists, and corticosteroids may reduce the incidence and intensity of infusion reactions ",
                        "Infusion reactions may begin within minutes of infusion, although symptoms may continue to intensify and not peak for several hours after completion of infusion",
                        "Monitor during infusion and discontinue for severe reactions ",
                        "When a reaction occurs, pause infusion, and institute supportive care as needed ",
                        "Contraindicated in patients with known allergy to dimethyl sulfoxide (DMSO), Dextran 40, gentamicin, human serum albumin, or bovine material "
                    ]
                },
                {
                    "type": "Graft versus host disease",
                    "description": [
                        "GVHD may be fatal ",
                        "Administering immunosuppressive therapy may decrease risk of GVHD ",
                        "Monitor for signs and symptoms of GVHD, and treat if GVHD develops"
                    ]
                },
                {
                    "type": "Engraftment syndrome",
                    "description": [
                        "Engraftment syndrome may be fatal ",
                        "Promptly treat engraftment syndrome with corticosteroids "
                    ]
                },
                {
                    "type": "Graft failure",
                    "description": [
                        "Graft failure may be fatal ",
                        "Primary graft failure is defined as failure to achieve an absolute neutrophil count >500 per microliter blood by day 42 after transplantation",
                        "Monitor for evidence of hematopoietic recovery "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Known sensitivity to dimethyl sulfoxide (DMSO), Dextran 40, gentamicin, human serum albumin or bovine material"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Infusion reactions occurred following infusion, including hypertension, mucosal inflammation, dysphagia, dyspnea, vomiting and gastrointestinal toxicity; monitor for signs and symptoms of infusion reactions during and after administration",
                "Acute and chronic GVHD, including life-threatening and fatal cases, occurred following treatment; acute GVHD manifests as maculopapular rash, gastrointestinal symptoms, and elevated bilirubin level",
                "Primary graft failure occurred; immunologic rejection is primary cause of graft failure",
                "Engraftment syndrome may occur; monitor for unexplained fever, rash, hypoxemia, weight gain, and pulmonary infiltrates in the periengraftment period; treat with corticosteroids as soon as engraftment syndrome is recognized, to ameliorate symptoms; if untreated, engraftment syndrome may progress to multiorgan failure and death"
            ],
            "specific": [
                {
                    "type": "Transmission of serious infections",
                    "description": [
                        "Transmission of infectious disease may occur",
                        "Disease may be caused by known or unknown infectious agents",
                        "Screen donors for increased risk of infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV), ",
                        "Treponema pallidum",
                        ", West Nile Virus (WNV), transmissible spongiform encephalopathy (TSE) agents, vaccinia, and Zika virus (for umbilical cord blood collected since March 2016)",
                        "Also screen donors for clinical evidence of sepsis and communicable disease risks associated with xenotransplantation",
                        "Test maternal blood samples for HIV types 1 and 2, HTLV types I and II, HBV, HCV, T pallidum, and WNV",
                        "Testing of maternal and infant donor blood is also performed for evidence of donor infection due to cytomegalovirus",
                        "Test results may be found on container label and/or in accompanying records",
                        "Report occurrence of transmitted infection to Gamida Cell at (844) 477-7478",
                        "These measures do not totally eliminate risk of transmitting infectious diseases and disease agents"
                    ]
                },
                {
                    "type": "Transmission of rare genetic diseases",
                    "description": [
                        "May transmit rare genetic diseases involving the hematopoietic system ",
                        "Screen cord blood donors to exclude donors with sickle cell disease, and anemias due to abnormalities in hemoglobins C, D, and E",
                        "Because of the age of donor at time cord blood collection takes place, the ability to exclude rare genetic diseases is severely limited"
                    ]
                },
                {
                    "type": "Allergic reactions",
                    "description": [
                        "Allergic reactions may occur",
                        "Reactions include bronchospasm, wheezing, angioedema, pruritus, and hives",
                        "Serious hypersensitivity reactions, including anaphylaxis, may be due to DMSO, residual gentamicin, Dextran 40, human serum albumin (HSA), and bovine material in omidubicel",
                        "May also contain residual antibiotics if cord blood donor was exposed to antibiotics in utero",
                        "Monitor patients with a history of allergic reactions to antibiotics for allergic reactions after administering"
                    ]
                },
                {
                    "type": "Malignancies of donor origin",
                    "description": [
                        "Two treated patients developed post-transplant lymphoproliferative disorder (PTLD) in the second year post-transplant",
                        "PTLD manifests as a lymphoma-like disease favoring non-nodal sites",
                        "PTLD is usually fatal if not treated",
                        "Etiology is thought to be donor lymphoid cells transformed by Epstein-Barr virus (EBV)",
                        "Serial monitoring of blood for EBV DNA may be warranted in patients with persistent cytopenias",
                        "One treated patient developed a donor-cell derived myelodysplastic syndrome (MDS) during the fourth year posttransplant",
                        "Natural history is presumed to be the same as that for de novo MDS",
                        "Monitor life-long for secondary malignancies",
                        "In event that a secondary malignancy occurs after treatment, contact Gamida Cell at (844) 477-7478"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Magnesium decreased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "94"
        },
        {
            "name": "Viral infections",
            "percent": "1-3"
        },
        {
            "name": "Grade",
            "percent": "75"
        },
        {
            "name": "Bacterial infections",
            "percent": "1-3"
        },
        {
            "name": "Grade",
            "percent": "65"
        },
        {
            "name": "Acute GVHD",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "62"
        },
        {
            "name": "AST increased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "56"
        },
        {
            "name": "ALT increased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "56"
        },
        {
            "name": "Creatinine increased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "50"
        },
        {
            "name": "Bilirubin increased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "42"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "42"
        },
        {
            "name": "Chronic GVHD",
            "percent": "35"
        },
        {
            "name": "Pain",
            "percent": "33"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "31"
        },
        {
            "name": "Hypertension",
            "percent": "25"
        },
        {
            "name": "Fungal infections",
            "percent": "1-3"
        },
        {
            "name": "Grade",
            "percent": "21"
        },
        {
            "name": "Disease relapse",
            "percent": "21"
        },
        {
            "name": "Gastrointestinal toxicity",
            "percent": "19"
        },
        {
            "name": "Magnesium increased",
            "percent": "1-4"
        },
        {
            "name": "Grade",
            "percent": "15"
        },
        {
            "name": "Hemorrhage",
            "percent": "12"
        },
        {
            "name": "Dysphagia",
            "percent": "12"
        },
        {
            "name": "Renal impairment",
            "percent": "12"
        },
        {
            "name": "Respiratory failure",
            "percent": "12"
        },
        {
            "name": "Dyspnea",
            "percent": "8"
        },
        {
            "name": "Fatigue",
            "percent": "4"
        },
        {
            "name": "Graft failure",
            "percent": "2"
        },
        {
            "name": "Fever",
            "percent": "2"
        }
    ]
}